天津医药

天津医药 ›› 2022, Vol. 50 ›› Issue (11): 1209-1212.doi: 10.11958/20220383

• 药物临床观察 • 上一篇    下一篇

静脉注射氟比洛芬酯联合纳布啡用于眼眶减压术患者的术后镇痛效果

陈贻人1(), 郑雅静1, 陈樱2   

  1. 1 中山大学中山眼科中心海南眼科医院麻醉科（邮编570311）
    2 中山大学中山眼科中心麻醉科
  • 收稿日期:2022-03-14 修回日期:2020-05-20 出版日期:2022-11-15 发布日期:2022-11-11
  • 作者简介:陈贻人（1975），男，副主任医师，主要从事眼科手术麻醉方面研究。E-mail：chen1975yr@163.com
  • 基金资助:
    海南省自然科学基金资助项目(821MS0839)

Postoperative analgesic effect of intravenous flurbiprofen axetil combined with nalbuphine in patients undergoing orbital decompression

CHEN Yiren1(), ZHENG Yajing1, CHEN Ying2   

  1. 1 Department of Anesthesiology, Hainan Eye Hospital, Zhongshan Ophthalmic Center, Sun Yat-sen University, Haikou 570311, China
    2 Department of Anesthesiology, Zhongshan Ophthalmic Center, Sun Yat-sen University
  • Received:2022-03-14 Revised:2020-05-20 Published:2022-11-15 Online:2022-11-11

RichHTML

2

PDF (PC)

1786

摘要：

目的 评估静脉注射氟比洛芬酯联合纳布啡用于眼眶减压术患者的术后镇痛效果。方法 纳入拟行眼眶减压术的患者共计120例，根据随机数字表法分为氟比洛芬酯组（F组）、纳布啡组（N组）和氟比洛芬酯联合纳布啡组（F+N组），每组40例。所有患者于手术结束后即刻静脉注射镇痛药物。F组患者静脉注射氟比洛芬酯100 mg；N组患者静脉注射纳布啡0.1 mg/kg；F+N组患者静脉注射上述2种药物。使用数字评价量表（NRS）和Ramsay镇静评分评估3组患者返回病房后即刻（T0）、术后2 h（T2）、术后12 h（T12）的疼痛和镇静情况。记录患者术后24 h内低血压、恶心、呕吐、寒战、呼吸抑制、瘙痒等不良反应发生情况。结果 最终共纳入116例患者，F组、N组、F+N组分别纳入38例、38例、40例患者。F+N组患者T0时点、T2时点NRS评分显著低于F组和N组患者（P<0.05），3组患者T12时点NRS评分的比较差异无统计学意义（P>0.05）。3组患者T0、T2、T12时点Ramsay镇静评分的比较差异均无统计学意义（P>0.05）。3组间低血压、恶心、呕吐、寒战、呼吸抑制及瘙痒发生率比较差异无统计学意义（均P>0.05）。结论 术中静脉注射氟比洛芬酯联合纳布啡能够为眼眶减压术患者提供良好的术后镇痛效果且安全性较高。

关键词: Graves眼病, 纳布啡, 氟比洛芬酯, 眼眶减压术, 术后镇痛

Abstract:

Objective To evaluate the postoperative analgesic effect of intravenous flurbiprofen axetil combined with nalbuphine in patients undergoing orbital decompression. Methods A total of 120 patients who planned to undergo orbital decompression in our hospital were included. Patients were randomly divided into the flurbiprofen group (F group), the nalbuphine group (N group) and the flurbiprofen combined nalbuphine group (F+N group) with 40 patients in each group. All patients were given analgesic drugs intravenously immediately after the operation. Patients in the F group were intravenously injected 100 mg flurbiprofen axetil, patients in the N group were intravenously injected with nalbuphine 0.1 mg/kg and patients in the F+N group were intravenously injected with flurbiprofen axetil 100 mg and nalbuphine 0.1 mg/kg. The Numerical Rating Scale (NRS) and Ramsay sedation score were used to evaluate pain and sedation of patients in the three groups immediately after returning to ward (T0), 2 h (T2) and 12 h (T12) after surgery. Adverse reactions including the incidence of hypotension, nausea, vomiting, shivering, respiratory depression and pruritus were recorded within 24 hours of operation. Results A total of 116 patients were eventually enrolled, including 38 patients in the F group, 38 patients in the N group and 40 patients in the F+N group, respectively. NRS scores at T0 and T2 were significantly lower in the F+N group than those in the F group and the N group (P<0.05). There was no significant difference in NRS score at T12 between the three groups (P>0.05). There were no significant differences in Ramsay sedation scores at T0, T2 and T12 between the 3 groups (P>0.05). In terms of adverse reactions, there were no significant differences in the incidence of hypotension, nausea, vomiting, shivering, respiratory depression and pruritus between the three groups (P>0.05). Conclusion Intraoperative intravenous flurbiprofen axetil combined with nalbuphine can provide better postoperative analgesic effect and higher safety for patients undergoing orbital decompression.

Key words: Graves ophthalmopathy, nalbuphine, flurbiprofen axetil, orbital decompression, postoperative analgesia

中图分类号: